Related Experiment Video

Updated: Aug 9, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

[Use of beta-blockader visken in children with primary arterial hypertension]

E A Nadezhdina, I N Vul'fson, I N Ivanitskaia

    Kardiologiia
    |May 1, 1976
    PubMed

    Insights

    Visken (pindolol) treatment for primary arterial hypertension in children showed varied effects on cardiovascular parameters. Individual responses and potential side effects were observed even at low doses.

    Area of Science:

    • Pediatric Cardiology
    • Pharmacology
    • Hypertension Research

    Context:

    • Primary arterial hypertension in children (Stage IB) presents unique challenges.
    • Assessing the efficacy and safety of antihypertensive medications in pediatric populations is crucial.
    • Understanding cardiovascular dynamics in pediatric hypertension is an ongoing area of research.

    Purpose:

    • To evaluate the effects of Visken (pindolol) on children with Stage IB primary arterial hypertension.
    • To analyze the drug's impact on general state, cardiac function, arterial pressure, cardiac output, and vascular resistance.
    • To identify individual patient responses and potential adverse effects of Visken therapy.

    Summary:

    • A 6-8 week treatment course of Visken was administered to 28 children with primary arterial hypertension.
    • The study observed a diverse range of effects on the children's general condition and circulatory system parameters.
    • Individual variability in the response of cardiac contractions, arterial pressure, cardiac output, and peripheral resistance to Visken was noted.

    Impact:

    • Visken's effect on pediatric hypertension is highly individualized.
    • Even low doses of Visken can lead to the development of side effects.
    • This study highlights the need for careful monitoring during Visken treatment in children.

    More Related Videos

    Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound10:09

    Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

    Published on: August 4, 2022

    In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus11:59

    In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus

    Published on: April 28, 2023

    Related Concept Videos

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
    Antihypertensive Drugs: Action of β1 Blockers01:17

    Antihypertensive Drugs: Action of β1 Blockers

    β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
    Antihypertensive Drugs: Types of β-Blockers01:28

    Antihypertensive Drugs: Types of β-Blockers

    β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...